{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:41:48Z","timestamp":1764002508927,"version":"3.37.3"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2020","PTDC\/QUI-NUC\/ 30147\/2017)"],"award-info":[{"award-number":["UID\/Multi\/04349\/2020","PTDC\/QUI-NUC\/ 30147\/2017)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Imaging"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40336-021-00477-2","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T03:02:46Z","timestamp":1641870166000},"page":"123-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical application of radioiodinated antibodies: where are we?"],"prefix":"10.1007","volume":"10","author":[{"given":"Maria Cristina","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o D. G.","family":"Correia","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"477_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497. https:\/\/doi.org\/10.1038\/256495a0","journal-title":"Nature"},{"key":"477_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","volume":"17","author":"H Shepard","year":"2017","unstructured":"Shepard H, Phillips G, Thanos C, Feldnnann M (2017) Developments in therapy with monoclonal antibodies and related proteins. Clin Med 17:220\u2013232. https:\/\/doi.org\/10.7861\/clinmedicine.17-3-220","journal-title":"Clin Med"},{"key":"477_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0592-z","author":"R Lu","year":"2020","unstructured":"Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H et al (2020) Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. https:\/\/doi.org\/10.1186\/s12929-019-0592-z","journal-title":"J Biomed Sci"},{"key":"477_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1089\/cbr.2013.1523","volume":"28","author":"M Jain","year":"2013","unstructured":"Jain M, Gupta S, Kaur S, Ponnusamy M, Batra S (2013) Emerging trends for radioimmunotherapy in solid tumours. Cancer Biother Radiopharm 28:639\u2013650. https:\/\/doi.org\/10.1089\/cbr.2013.1523","journal-title":"Cancer Biother Radiopharm"},{"key":"477_CR5","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","volume":"13","author":"M Jain","year":"2007","unstructured":"Jain M, Venkatraman G, Batra S (2007) Optimization of Radioimmunotherapy of solid tumours: biological impediments and their modulation. Clin Cancer Res 13:1374\u20131382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2436","journal-title":"Clin Cancer Res"},{"key":"477_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1148\/radiology.167.1.3347742","volume":"167","author":"J Carrasquillo","year":"1988","unstructured":"Carrasquillo J, Sugarbaker P, Colcher D, Reynolds J, Esteban J, Bryant G et al (1988) Peritoneal carcinomatosis-Imaging with intraperitoneal injection of i\u2013131-labeled b723 monoclonal-antibody. Radiology 167:35\u201340. https:\/\/doi.org\/10.1148\/radiology.167.1.3347742","journal-title":"Radiology"},{"key":"477_CR7","first-page":"6363","volume":"51","author":"D Milenic","year":"1991","unstructured":"Milenic D, Yokota T, Filpula D, Finkelman M, Dodd S, Wood J et al (1991) Construction, binding-properties, metabolism, and tumour targeting of a single-chain FV derived from the pancarcinoma monoclonal-antibody CC49. Can Res 51:6363\u20136371 (PMID: 1933899)","journal-title":"Can Res"},{"key":"477_CR8","first-page":"2330","volume":"50","author":"R Sharkey","year":"1990","unstructured":"Sharkey R, Mottahennessy C, Pawlyk D, Siegel J, Goldenberg D (1990) Biodistribution and radiation-dose estimates for yttrium-labeled and iodine-labeled monoclonal-antibody IGG and fragments in nude-mice bearing human colonic tumour xenografts. Cancer Res 50:2330\u20132336","journal-title":"Cancer Res"},{"key":"477_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/imt.10.114|10.2217\/IMT.10.114","volume":"3","author":"R Sharkey","year":"2011","unstructured":"Sharkey R, Goldenberg D (2011) Cancer radioimmunotherapy. Immunotherapy 3:349\u2013370. https:\/\/doi.org\/10.2217\/imt.10.114|10.2217\/IMT.10.114","journal-title":"Immunotherapy"},{"key":"477_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","volume":"9","author":"W Strohl","year":"2018","unstructured":"Strohl W (2018) Current progress in innovative engineered antibodies. Protein Cell 9:86\u2013120. https:\/\/doi.org\/10.1007\/s13238-017-0457-8","journal-title":"Protein Cell"},{"key":"477_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0958-1669(02)00352-X","volume":"13","author":"S Batra","year":"2002","unstructured":"Batra S, Jain M, Wittel U, Chauhan S, Colcher D (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603\u2013608. https:\/\/doi.org\/10.1016\/S0958-1669(02)00352-X","journal-title":"Curr Opin Biotechnol"},{"key":"477_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1517\/14712598.4.2.217","volume":"4","author":"M Russeva","year":"2004","unstructured":"Russeva M, Adams G (2004) Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther 4:217\u2013231. https:\/\/doi.org\/10.1517\/14712598.4.2.217","journal-title":"Expert Opin Biol Ther"},{"key":"477_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","volume":"38","author":"A Kassis","year":"2008","unstructured":"Kassis A (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38:358\u2013366. https:\/\/doi.org\/10.1053\/j.semnuclmed.2008.05.002","journal-title":"Semin Nucl Med"},{"key":"477_CR14","first-page":"2229","volume":"36","author":"R Meredith","year":"1995","unstructured":"Meredith R, Khazaeli M, Plott W, Spencer S, Wheeler R, Brady L et al (1995) Initial clinical-evaluation of iodine-125-labeled chimeric 17\u20131A for metastatic colon-cancer. J Nucl Med 36:2229\u20132233 (PMID: 8523110)","journal-title":"J Nucl Med"},{"key":"477_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000417788","volume":"24","author":"A Markoe","year":"1990","unstructured":"Markoe A, Brady L, Woo D, Amendola B, Karlsson U, Fisher M et al (1990) Treatment of gastrointestinal cancer using monoclonal antibodies. Front Radiat Ther Oncol 24:214\u2013224. https:\/\/doi.org\/10.1159\/000417788","journal-title":"Front Radiat Ther Oncol"},{"key":"477_CR16","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/JCO.1996.14.6.1787","volume":"14","author":"S Welt","year":"1996","unstructured":"Welt S, Scott A, Divgi C, Kemeny N, Finn R, Daghighian F et al (1996) Phase I\/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14:1787\u20131797. https:\/\/doi.org\/10.1200\/JCO.1996.14.6.1787","journal-title":"J Clin Oncol"},{"key":"477_CR17","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.2967\/jnumed.109.066993","volume":"50","author":"L Santoro","year":"2009","unstructured":"Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki P et al (2009) Noninternalizing monoclonal antibodies are suitable candidates for I-125 radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 50:2033\u20132041. https:\/\/doi.org\/10.2967\/jnumed.109.066993","journal-title":"J Nucl Med"},{"key":"477_CR18","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149:778\u2013789. https:\/\/doi.org\/10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"key":"477_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.2910390306","volume":"39","author":"S Miotti","year":"1987","unstructured":"Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa S et al (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal-antibodies with tumour-restricted specificity. Int J Cancer 39:297\u2013303. https:\/\/doi.org\/10.1002\/ijc.2910390306","journal-title":"Int J Cancer"},{"key":"477_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0959-8049(94)90257-7","volume":"30A","author":"L Mantovani","year":"1994","unstructured":"Mantovani L, Miotti S, Menard S, Canevari S, Raspagliesi F, Bottini C et al (1994) Folate binding-protein distribution in normal-tissues and biological-fluids from ovarian-carcinoma patients as detected by the monoclonal-antibodies MOV18 and MOV19. Eur J Cancer 30A:363\u2013369. https:\/\/doi.org\/10.1016\/0959-8049(94)90257-7","journal-title":"Eur J Cancer"},{"key":"477_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/030089168907500524","volume":"75","author":"R Veggian","year":"1989","unstructured":"Veggian R, Fasolato S, Menard S, Minucci D, Pizzetti P, Regazzoni M et al (1989) Immunohistochemical reactivity of a monoclonal-antibody prepared against human ovarian-carcinoma on normal and pathological female genital tissues. Tumouri 75:510\u2013513","journal-title":"Tumouri"},{"key":"477_CR22","first-page":"665","volume":"37","author":"P Li","year":"1996","unstructured":"Li P, DelVecchio S, Fonti R, Carriero M, Potena M, Botti G et al (1996) Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J Nucl Med 37:665\u2013672 (PMID: 2481353)","journal-title":"J Nucl Med"},{"key":"477_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/0277-5379(91)90174-C","volume":"27","author":"F Crippa","year":"1991","unstructured":"Crippa F, Buraggi G, Dire E, Gasparini M, Seregni E, CanevarI S et al (1991) Radioimmunoscintigraphy of ovarian-cancer with the MOV18 monoclonal-antibody. Eur J Cancer 27:724\u2013729. https:\/\/doi.org\/10.1016\/0277-5379(91)90174-C","journal-title":"Eur J Cancer"},{"key":"477_CR24","first-page":"2000","volume":"33","author":"C Molthoff","year":"1992","unstructured":"Molthoff C, Buist M, Kenemans P, Pinedo H, Boven E (1992) Experimental and clinical analysis of the characteristics of a chimeric monoclonal-antibody, MOV18, reactive with an ovarian cancer-associated antigen. J Nucl Med 33:2000\u20132005","journal-title":"J Nucl Med"},{"key":"477_CR25","first-page":"5413","volume":"53","author":"M Buist","year":"1993","unstructured":"Buist M, Kenemans P, Denhollander W, Vermorken J, Molthoff C, Burger C et al (1993) Kinetics and tissue distribution of the radiolabeled chimeric monoclonal-antibody MOV18 IGG and F(AB\u2019)(2) fragments in ovarian-carcinoma patients. Can Res 53:5413\u20135418","journal-title":"Can Res"},{"key":"477_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/0959-8049(94)00454-D","volume":"31A","author":"F Crippa","year":"1995","unstructured":"Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C et al (1995) single-dose intraperitoneal radioimmunotherapy with the murine monoclonal-antibody I-131 MOV18 - Clinical-results in patients with minimal residual disease of ovarian-cancer. Eur J Cancer 31A:686\u2013690. https:\/\/doi.org\/10.1016\/0959-8049(94)00454-D","journal-title":"Eur J Cancer"},{"key":"477_CR27","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2712::AID-CNCR50>3.0.CO;2-B","volume":"80","author":"C Molthoff","year":"1997","unstructured":"Molthoff C, Prinssen H, Kenemans P, van Hof A, den Hollander W, Verheijen R (1997) Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study. Cancer 80:2712\u20132720. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19971215)80:12+%3c2712::AID-CNCR50%3e3.0.CO;2-B","journal-title":"Cancer"},{"key":"477_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1023\/A:1008296202198","volume":"8","author":"R van Rijswijk","year":"1997","unstructured":"van Rijswijk R, Hoekman K, Burger C, Verheijen R, Vermorken J (1997) Experience with intraperitoneal cisplatin and etoposide and iv sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol 8:1235\u20131241. https:\/\/doi.org\/10.1023\/A:1008296202198","journal-title":"Ann Oncol"},{"key":"477_CR29","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s002590050335","volume":"25","author":"W Buijs","year":"1998","unstructured":"Buijs W, Tibben J, Boerman O, Molthoff C, Massuger L, Koenders E et al (1998) Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med 25:1552\u20131561. https:\/\/doi.org\/10.1007\/s002590050335","journal-title":"Eur J Nucl Med"},{"key":"477_CR30","doi-asserted-by":"publisher","unstructured":"Van Zantenr-Pzybysz I, Molthoff C, Roos J, Verheijen R, Van Hof A, Buist M, et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MO: I.v. vs. i.p. Int J Cancer. 2001;92:106\u201314. doi:https:\/\/doi.org\/10.1002\/1097-0215(200102)9999:9999<::AID-IJC1145>3.0.CO;2-I.","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1145>3.0.CO;2-I"},{"key":"477_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1023\/A:1011379725811","volume":"6","author":"S Gendler","year":"2001","unstructured":"Gendler S (2001) MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6:339\u2013353. https:\/\/doi.org\/10.1023\/A:1011379725811","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"477_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00002371-200301000-00006","volume":"26","author":"P Mukherjee","year":"2003","unstructured":"Mukherjee P, Madsen C, Ginardi A, Tinder T, Jacobs T, Parker J et al (2003) Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26:47\u201362. https:\/\/doi.org\/10.1097\/00002371-200301000-00006","journal-title":"J Immunother"},{"key":"477_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(82)90046-0","volume":"2","author":"A Epenetos","year":"1982","unstructured":"Epenetos A, Mather S, Granowska M, Nimmon C, Hawkins L, Britton K et al (1982) Targeting of iodine-123-labeled tumour-associated monoclonal-antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 2:999\u20131005","journal-title":"Lancet"},{"key":"477_CR34","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/1097-0142(19850301)55:5%3C984::AID-CNCR2820550511%3E3.0.CO;2-E","volume":"55","author":"A Epenetos","year":"1985","unstructured":"Epenetos A, Shepherd J, Britton K, Mather S, Taylor-Papadimitriou J, Granowska M et al (1985) I-123 Radioiodinated antibody imaging of occult ovarian-cancer. Cancer 55:984\u2013987. https:\/\/doi.org\/10.1002\/1097-0142(19850301)55:5%3C984::AID-CNCR2820550511%3E3.0.CO;2-E","journal-title":"Cancer"},{"key":"477_CR35","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1200\/JCO.1987.5.12.1890","volume":"5","author":"A Epenetos","year":"1987","unstructured":"Epenetos A, Munro A, Stewart S, Rampling R, Lambert H, Mckenzie C et al (1987) Antibody-guided irradiation of advanced ovarian-cancer with intraperitoneally administered radiolabeled monoclonal-antibodies. J Clin Oncol 5:1890\u20131899. https:\/\/doi.org\/10.1200\/JCO.1987.5.12.1890","journal-title":"J Clin Oncol"},{"key":"477_CR36","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1118\/1.595559","volume":"11","author":"B Wessels","year":"1984","unstructured":"Wessels B, Rogus R (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumour associated antibodies. Med Phys 11:638\u2013645. https:\/\/doi.org\/10.1118\/1.595559","journal-title":"Med Phys"},{"key":"477_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bjc.1993.349","volume":"68","author":"V Hird","year":"1993","unstructured":"Hird V, Maraveyas A, Snook D, Dhokia B, Soutter W, Meares C et al (1993) Adjuvant therapy of ovarian-cancer with radioactive monoclonal-antibody. Br J Cancer 68:403\u2013406. https:\/\/doi.org\/10.1038\/bjc.1993.349","journal-title":"Br J Cancer"},{"key":"477_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","volume":"24","author":"R Verheijen","year":"2006","unstructured":"Verheijen R, Massuger L, Benigno B, Epenetos A, Lopes A, Soper J et al (2006) Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24:571\u2013578. https:\/\/doi.org\/10.1200\/JCO.2005.02.5973","journal-title":"J Clin Oncol"},{"key":"477_CR39","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1002\/ijc.22663","volume":"120","author":"A Oei","year":"2007","unstructured":"Oei A, Verheijen R, Seiden M, Benigno B, Lopes A, Soper J et al (2007) Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 120:2710\u20132714. https:\/\/doi.org\/10.1002\/ijc.22663","journal-title":"Int J Cancer"},{"key":"477_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/hyb.1995.14.199","volume":"14","author":"R Madiyalakan","year":"1995","unstructured":"Madiyalakan R, Sykes T, Dharampaul S, Sykes C, Baum R, Hor G et al (1995) Antiidiotype induction therapy - evidence for the induction of immune-response through the idiotype network in patients with ovarian-cancer after administration of anti-CA125 murine monoclonal-antibody B43.13. Hybridoma 14:199\u2013203. https:\/\/doi.org\/10.1089\/hyb.1995.14.199","journal-title":"Hybridoma"},{"key":"477_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ijc.2910420311","volume":"42","author":"K Moseley","year":"1988","unstructured":"Moseley K, Battaile A, Knapp R, Haisma H (1988) Localization of radiolabeled f(ab\u2019)2 fragments of monoclonal-antibodies in nude-mice bearing intraperitoneally growing human ovarian-cancer xenografts. Int J Cancer 42:368\u2013372. https:\/\/doi.org\/10.1002\/ijc.2910420311","journal-title":"Int J Cancer"},{"key":"477_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0002-9378(88)80150-9","volume":"159","author":"H Haisma","year":"1988","unstructured":"Haisma H, Moseley K, Battaile A, Griffiths T, Knapp R (1988) Distribution and pharmacokinetics of radiolabeled monoclonal-antibody OC-125 After intravenous and intraperitoneal administration in gynecologic tumours. Am J Obstet Gynecol 159:843\u2013848. https:\/\/doi.org\/10.1016\/S0002-9378(88)80150-9","journal-title":"Am J Obstet Gynecol"},{"key":"477_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0090-8258(89)90169-8","volume":"34","author":"N Finkler","year":"1989","unstructured":"Finkler N, Muto M, Kassis A, Weadock K, Tumeh S, Zurawski V et al (1989) Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian-cancer. Gynecol Oncol 34:339\u2013344. https:\/\/doi.org\/10.1016\/0090-8258(89)90169-8","journal-title":"Gynecol Oncol"},{"key":"477_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0090-8258(92)90302-Y","volume":"45","author":"M Muto","year":"1992","unstructured":"Muto M, Finkler N, Kassis A, Howes A, Anderson L, Lau C et al (1992) Intraperitoneal radioimmunotherapy of refractory ovarian-carcinoma utilizing iodine-131-labeled monoclonal-antibody OC125. Gynecol Oncol 45:265\u2013272. https:\/\/doi.org\/10.1016\/0090-8258(92)90302-Y","journal-title":"Gynecol Oncol"},{"key":"477_CR45","first-page":"3249S","volume":"5","author":"M Mahe","year":"1999","unstructured":"Mahe M, Fumoleau P, Fabbro M, Guastalla J, Faurous P, Chauvot P et al (1999) A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5:3249S-S3253","journal-title":"Clin Cancer Res"},{"key":"477_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0009-8981(78)90134-1","volume":"86","author":"F Benham","year":"1978","unstructured":"Benham F, Povey M, Harris H (1978) Placental-like alkaline-phosphatase in malignant and benign ovarian tumours. Clin Chim Acta 86:201\u2013215. https:\/\/doi.org\/10.1016\/0009-8981(78)90134-1","journal-title":"Clin Chim Acta"},{"key":"477_CR47","first-page":"4496","volume":"44","author":"C Sunderland","year":"1984","unstructured":"Sunderland C, Davies J, Stirrat G (1984) Immunohistology of normal and ovarian-cancer tissue with a monoclonal-antibody to placental alkaline-phosphatase. Can Res 44:4496\u20134502","journal-title":"Can Res"},{"key":"477_CR48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000011892","volume":"55","author":"C Kosmas","year":"1998","unstructured":"Kosmas C, Kalofonos H, Hird V, Epenetos A (1998) Monoclonal antibody targeting of ovarian carcinoma. Oncology 55:435\u2013446. https:\/\/doi.org\/10.1159\/000011892","journal-title":"Oncology"},{"key":"477_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1259\/0007-1285-59-698-117","volume":"59","author":"A Epenetos","year":"1986","unstructured":"Epenetos A, Carr D, Johnson P, Bodmer W, Lavender J (1986) Antibody-guided radiolocalization of tumours in patients with testicular or ovarian-cancer using 2 radioiodinated monoclonal-antibodies to placental alkaline-phosphatase. Br J Radiol 59:117\u2013125. https:\/\/doi.org\/10.1259\/0007-1285-59-698-117","journal-title":"Br J Radiol"},{"key":"477_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"477_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman S (1965) Specific carcinoembryonic antigens of human digestive system. J Exp Med 122:467. https:\/\/doi.org\/10.1084\/jem.122.3.467","journal-title":"J Exp Med"},{"key":"477_CR52","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1040-8428(85)80008-1","volume":"2","author":"J Shively","year":"1985","unstructured":"Shively J, Beatty J (1985) CEA-related antigens - molecular-biology and clinical-significance. CRC Crit Rev Oncol Hematol 2:355\u2013399. https:\/\/doi.org\/10.1016\/S1040-8428(85)80008-1","journal-title":"CRC Crit Rev Oncol Hematol"},{"key":"477_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1380-2933(98)00004-9","volume":"4","author":"L Hefta","year":"1998","unstructured":"Hefta L, Neumaier M, Shively J (1998) Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs. Immunotechnology 4:49\u201357. https:\/\/doi.org\/10.1016\/S1380-2933(98)00004-9","journal-title":"Immunotechnology"},{"key":"477_CR54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/bjc.1994.338","volume":"70","author":"D Lane","year":"1994","unstructured":"Lane D, Eagle K, Begent R, Hopestone L, Green A, Casey J et al (1994) Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labeled antibody to carcinoembryonic antigen - Phase I\/II study with comparative biodistribution of intact and F(ab\u2019)(2) antibodies. Br J Cancer 70:521\u2013525. https:\/\/doi.org\/10.1038\/bjc.1994.338","journal-title":"Br J Cancer"},{"key":"477_CR55","first-page":"316","volume":"24","author":"R Wahl","year":"1983","unstructured":"Wahl R, Parker C, Philpott G (1983) Improved radioimaging and tumour-localization with monoclonaL F(ab\u2019)2. J Nucl Med 24:316\u2013325","journal-title":"J Nucl Med"},{"key":"477_CR56","first-page":"1035","volume":"31","author":"F Buchegger","year":"1990","unstructured":"Buchegger F, Pelegrin A, Delaloye B, BischofdelaloyE A, Mach J (1990) Iodine-131-labeled mAb F(ab\u2019)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon-carcinoma grafted in nude-mice. J Nucl Med 31:1035\u20131044","journal-title":"J Nucl Med"},{"key":"477_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/bjc.1993.288","volume":"68","author":"R Pedley","year":"1993","unstructured":"Pedley R, Boden J, Boden R, Dale R, Begent R (1993) Comparative radioimmunotherapy using intact of F(ab\u2019)2 fragments of I-131 anti-CEA antibody in a colonic xenograft model. Br J Cancer 68:69\u201373. https:\/\/doi.org\/10.1038\/bjc.1993.288","journal-title":"Br J Cancer"},{"key":"477_CR58","first-page":"686","volume":"43","author":"F Primus","year":"1983","unstructured":"Primus F, Newell K, Blue A, Goldenberg D (1983) Immunological heterogeneity of carcinoembryonic antigen-antigenic determinants on carcinoembryonic antigen distinguished by monoclonal-antibodies. Can Res 43:686\u2013692","journal-title":"Can Res"},{"key":"477_CR59","first-page":"693","volume":"43","author":"F Primus","year":"1983","unstructured":"Primus F, Kuhns W, Goldenberg D (1983) Immunological heterogeneity of carcinoembryonic antigen\u2014immunohistochemical detection of carcinoembryonic antigen determinants in colonic tumours with monoclonal-antibodies. Can Res 43:693\u2013701","journal-title":"Can Res"},{"key":"477_CR60","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4049\/jimmunol.137.3.839","volume":"137","author":"P Burtin","year":"1986","unstructured":"Burtin P, Chavanel G, Hendrick J, Frenoy N (1986) Antigenic variants of the nonspecific cross-reacting antigen (NCA). J Immunol 137:839\u2013845","journal-title":"J Immunol"},{"key":"477_CR61","first-page":"2823","volume":"50","author":"R Sharkey","year":"1990","unstructured":"Sharkey R, Goldenberg D, Goldenberg H, Lee R, Ballance C, Pawlyk D et al (1990) murine monoclonal-antibodies against carcinoembryonic antigen\u2014immunological, pharmacokinetic, and targeting properties in humans. Can Res 50:2823\u20132831","journal-title":"Can Res"},{"key":"477_CR62","first-page":"858","volume":"38","author":"T Behr","year":"1997","unstructured":"Behr T, Sharkey R, Juweid M, Dunn R, Vagg R, Ying Z et al (1997) Phase I\/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38:858\u2013870","journal-title":"J Nucl Med"},{"key":"477_CR63","first-page":"735","volume":"37","author":"M Juweid","year":"1996","unstructured":"Juweid M, Sharkey R, Swayne L, Behr T, Dunn R, Goldenberg D (1996) Radioimmunotherapy in patients with CEA-producing cancers and small-volume disease using I-131-labeled anti-CEA monoclonal antibody NP-4 F(ab\u2019)(2). J Nucl Med 37:735","journal-title":"J Nucl Med"},{"key":"477_CR64","first-page":"61","volume":"34","author":"D Goldenberg","year":"1993","unstructured":"Goldenberg D, Wlodkowski T, Sharkey R, Silberstein E, Serafini A, Garty I et al (1993) Colorectal-cancer imaging with iodine-123-labeled CEA monoclonal-antibody fragments. J Nucl Med 34:61\u201370","journal-title":"J Nucl Med"},{"key":"477_CR65","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1002\/1097-0142(19930601)71:11<3478::AID-CNCR2820711104>3.0.CO;2-A","volume":"71","author":"H Hansen","year":"1993","unstructured":"Hansen H, Goldenberg D, Newman E, Grebenau R, Sharkey R (1993) Characterization of 2nd-generation monoclonal-antibodies against carcinoembryonic antigen. Cancer 71:3478\u20133485. https:\/\/doi.org\/10.1002\/1097-0142(19930601)71:11%3c3478::AID-CNCR2820711104%3e3.0.CO;2-A","journal-title":"Cancer"},{"key":"477_CR66","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/1097-0142(19930315)71:6<2082::AID-CNCR2820710625>3.0.CO;2-Q","volume":"71","author":"R Sharkey","year":"1993","unstructured":"Sharkey R, Goldenberg D, Murthy S, Pinsky H, Vagg R, Pawlyk D et al (1993) Clinical-evaluation of tumour targeting with a high-affinity, anticarcinoembryonic-antigen specific, murine monoclonal-antibody, MN-14. Cancer 71:2082\u20132096. https:\/\/doi.org\/10.1002\/1097-0142(19930315)71:6%3c2082::AID-CNCR2820710625%3e3.0.CO;2-Q","journal-title":"Cancer"},{"key":"477_CR67","first-page":"5935","volume":"55","author":"R Sharkey","year":"1995","unstructured":"Sharkey R, Juweid M, Shevitz J, Behr T, Dunn R, Swayne L et al (1995) Evaluation of a complementarity-determining region-grafted (humanized) anticarcinoembryonic antigen monoclonal-antibody in preclinical and clinical-studies. Cancer Res 55:5935\u201345","journal-title":"Cancer Res"},{"key":"477_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3816\/CCC.2002.n.009","volume":"2","author":"G Hajjar","year":"2002","unstructured":"Hajjar G, Sharkey RM, Burton J, Zhang C-H, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM (2002) Phase I radioimmunotherapy trial with iodine-131\u2014labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2:31\u201342","journal-title":"Clin Colorectal Cancer"},{"key":"477_CR69","first-page":"5403","volume":"48","author":"R Blumenthal","year":"1988","unstructured":"Blumenthal R, Sharkey R, Snyder D, Hansen H, Goldenberg D (1988) Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1. Can Res 48:5403\u20135406","journal-title":"Can Res"},{"key":"477_CR70","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208\u20131215. https:\/\/doi.org\/10.1016\/S1470-2045(13)70447-9","journal-title":"Lancet Oncol"},{"key":"477_CR71","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/SLA.0b013e3181b4539b","volume":"250","author":"M de Jong","year":"2009","unstructured":"de Jong M, Pulitano C, Ribero D, Strub J, Mentha G, Schulick R et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis an international multi-institutional analysis of 1669 patients. Ann Surg 250:440\u2013448. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b4539b","journal-title":"Ann Surg"},{"key":"477_CR72","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","volume":"23","author":"T Liersch","year":"2005","unstructured":"Liersch T, Meller J, Kulle B, Behr T, Markus P, Langer C et al (2005) Phase II trial of carcinoembryonic antigen radioimmunotherapy with I-131-labletuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 23:6763\u20136770. https:\/\/doi.org\/10.1200\/JCO.2005.18.622","journal-title":"J Clin Oncol"},{"key":"477_CR73","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1245\/s10434-006-9328-x","volume":"14","author":"T Liersch","year":"2007","unstructured":"Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg D (2007) Update of carcinoembryonic antigen radioimmunotherapy with (131)supercript stopI-Labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 14:2577\u20132590. https:\/\/doi.org\/10.1245\/s10434-006-9328-x","journal-title":"Ann Surg Oncol"},{"key":"477_CR74","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/cncr.30390","volume":"123","author":"C Sahlmann","year":"2017","unstructured":"Sahlmann C, Homayounfar K, Niessner M, Dyczkowski J, Conradi L, Braulke F et al (2017) Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: safety, feasibility, and long-term efficacy results of a prospective phase 2 study. Cancer 123:638\u2013649. https:\/\/doi.org\/10.1002\/cncr.30390","journal-title":"Cancer"},{"key":"477_CR75","first-page":"850","volume":"46","author":"V Johnson","year":"1986","unstructured":"Johnson V, Schlom J, Paterson A, Bennett J, Magnani J, Colcher D (1986) Analysis of a human tumour-associated glycoprotein (TAG-72) identified by monoclonal-antibody B72.3. Cancer Res 46:850\u20137","journal-title":"Cancer Res"},{"key":"477_CR76","first-page":"1291","volume":"50","author":"A Molinolo","year":"1990","unstructured":"Molinolo A, Simpson J, Thor A, Schlom J (1990) Enhanced tumour binding using immunohistochemical analyses by 2nd generation anti-tumour-associated glycoprotein-72 monoclonal-antibodies versus monoclonal antibody-B72.3 in human tissue. Cancer Res 50:1291\u20138","journal-title":"Cancer Res"},{"key":"477_CR77","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1073\/pnas.78.5.3199","volume":"78","author":"D Colcher","year":"1981","unstructured":"Colcher D, Hand P, Nuti M, Schlom J (1981) A spectrum of monoclonal-antibodies reactive with human mammary-tumour cellS. Proc Natl Acad Sci USA Biol Sci 78:3199\u20133203. https:\/\/doi.org\/10.1073\/pnas.78.5.3199","journal-title":"Proc Natl Acad Sci USA Biol Sci"},{"key":"477_CR78","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10434-000-0743-0","volume":"7","author":"CK Brown","year":"2000","unstructured":"Brown CK, Modzelewski RA, Johnson CS, Wong MKK (2000) A novel approach for the identification of unique tumour vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 7:743\u2013749. https:\/\/doi.org\/10.1007\/s10434-000-0743-0","journal-title":"Ann Surg Oncol"},{"key":"477_CR79","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/archsurg.1991.01410270095015","volume":"126","author":"A Cohen","year":"1991","unstructured":"Cohen A, Martin E, Lavery I, Daly J, Sardi A, Aitken D et al (1991) Radioimmunoguided surgery using I-125 B72.3 in patients with colorectal-cancer. Arch Surg 126:349\u201352","journal-title":"Arch Surg"},{"key":"477_CR80","first-page":"1133","volume":"31","author":"D Colcher","year":"1990","unstructured":"Colcher D, Milenic D, Ferroni P, Carrasquillo J, Reynolds J, Roselli M et al (1990) Invivo fate of monoclonal-antibody B723 in patients with colorectal-cancer. J Nucl Med 31:1133\u201342","journal-title":"J Nucl Med"},{"key":"477_CR81","first-page":"1738","volume":"49","author":"D Colcher","year":"1989","unstructured":"Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D et al (1989) Characterization and biodistribution of recombinant and recombinant chimeric constructs of monoclonal-antibody B72.3. Cancer Res 49:1738\u201345","journal-title":"Cancer Res"},{"key":"477_CR82","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/protein\/1.6.499","volume":"1","author":"N Whittle","year":"1987","unstructured":"Whittle N, Adair J, Lloyd C, Jenkins L, Devine J, Schlom J et al (1987) Expression in cos cells of a mouse human chimaeric B723-antibody. Protein Eng 1:499\u2013505. https:\/\/doi.org\/10.1093\/protein\/1.6.499","journal-title":"Protein Eng"},{"key":"477_CR83","first-page":"23","volume":"33","author":"R Meredith","year":"1992","unstructured":"Meredith R, Khazaeli M, Plott W, Saleh M, Liu T, Allen L et al (1992) Phase-I trial of iodine-131-chimeric B723 (human IGG4) in metastatic colorectal-cancer. J Nucl Med 33:23\u20139","journal-title":"J Nucl Med"},{"key":"477_CR84","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1126\/science.3929380","volume":"229","author":"S Morrison","year":"1985","unstructured":"Morrison S (1985) Transfectomas provide novel chimeric antibodies. Science 229:1202\u20131207. https:\/\/doi.org\/10.1126\/science.3929380","journal-title":"Science"},{"key":"477_CR85","first-page":"181","volume":"51","author":"P Hutzell","year":"1991","unstructured":"Hutzell P, Kashmiri S, Colcher D, Primus F, Hand P, Roselli M et al (1991) Generation and characterization of a recombinant\/chimeric B72.3 (human gamma-1). Cancer Res 51:181\u20139","journal-title":"Cancer Res"},{"key":"477_CR86","first-page":"4588","volume":"48","author":"R Muraro","year":"1988","unstructured":"Muraro R, Kuroki M, Wunderlich D, Poole D, Colcher D, Thor A et al (1988) Generation and characterization of B72.3 2nd-generation monoclonal-antibodies reactive with the tumour-associated glycoprotein-72 antigen. Cancer Res 48:4588\u201396","journal-title":"Cancer Res"},{"key":"477_CR87","first-page":"4597","volume":"48","author":"D Colcher","year":"1988","unstructured":"Colcher D, Minelli M, Roselli M, Muraro R, Simpsonmilenic D, Schlom J (1988) Radioimmunolocalization of human carcinoma xenografts with B723 2nd-generation monoclonal-antibodies. Cancer Res 48:4597\u2013603","journal-title":"Cancer Res"},{"key":"477_CR88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0969-8051(94)90124-4","volume":"21","author":"C Divgi","year":"1994","unstructured":"Divgi C, Scott A, Mcdermott K, Fallone P, Hilton S, Siler K et al (1994) clinical comparison of radiolocalization of 2 monoclonal-antibodies (mAbs) against the TAG-72 antigen. Nucl Med Biol 21:9\u201315. https:\/\/doi.org\/10.1016\/0969-8051(94)90124-4","journal-title":"Nucl Med Biol"},{"key":"477_CR89","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/1097-0142(19940201)73:3+<1057::AID-CNCR2820731345>3.0.CO;2-3","volume":"73","author":"J Murray","year":"1994","unstructured":"Murray J, Macey D, Kasi L, Rieger P, Cunningham J, Bhadkamkar V et al (1994) Phase-II radioimmunotherapy trial with I-131 CC49 in colorectal-cancer. Cancer 73:1057\u20131066. https:\/\/doi.org\/10.1002\/1097-0142(19940201)73:3+%3c1057::AID-CNCR2820731345%3e3.0.CO;2-3","journal-title":"Cancer"},{"key":"477_CR90","first-page":"586","volume":"36","author":"C Divgi","year":"1995","unstructured":"Divgi C, Scott A, Dantis L, Capitelli P, Siler K, Hilton S et al (1995) Phase-I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon-carcinoma. J Nucl Med 36:586\u2013592","journal-title":"J Nucl Med"},{"key":"477_CR91","first-page":"3208","volume":"44","author":"J Greiner","year":"1984","unstructured":"Greiner J, Hand P, Noguchi P, Fisher P, Pestka S, Schlom J (1984) Enhanced expression of surface tumour-associated antigens on human-breast and colon-tumour cells after recombinant human-leukocyte alpha-interferon treatment. Can Res 44:3208\u20133214","journal-title":"Can Res"},{"key":"477_CR92","first-page":"4155","volume":"51","author":"J Greiner","year":"1991","unstructured":"Greiner J, Guadagni F, Goldstein D, Borden E, Ritts R, Witt P et al (1991) Evidence for the elevation of serum carcinoembryonic antigen and tumour-associated glycoprotein-72 levels in patients administered interferons. Can Res 51:4155\u20134163","journal-title":"Can Res"},{"key":"477_CR93","first-page":"600","volume":"53","author":"J Greiner","year":"1993","unstructured":"Greiner J, Ullmann C, Nieroda C, Qi C, Eggensperger D, Shimada S et al (1993) Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal-antibody (I-131-CC49) when given in combination with gamma-interferon. Can Res 53:600\u2013608","journal-title":"Can Res"},{"key":"477_CR94","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jnci\/84.6.399","volume":"84","author":"R Blumenthal","year":"1992","unstructured":"Blumenthal R, Sharkey R, Goldenberg D (1992) Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 84:399\u2013407. https:\/\/doi.org\/10.1093\/jnci\/84.6.399","journal-title":"J Natl Cancer Inst"},{"key":"477_CR95","first-page":"1017","volume":"35","author":"R Meredith","year":"1994","unstructured":"Meredith R, Bueschen A, Khazaeli M, Plott W, Grizzle W, Wheeler R et al (1994) treatment of metastatic prostate carcinoma with radiolabeled antibodY CC49. J Nucl Med 35:1017\u20131022","journal-title":"J Nucl Med"},{"key":"477_CR96","unstructured":"Wheeler RH MR, Saleh MN (1994) A phase II trial of IL-1+ radioimmunotherapy (RIT) in patients (pts) with metastatic colon cancer. Proc Annu Met Am Soc Clin Oncol (meeting abstract) 295"},{"key":"477_CR97","first-page":"1811","volume":"2","author":"R Meredith","year":"1996","unstructured":"Meredith R, Khazaeli M, Plott W, Grizzle W, Liu T, Schlom J et al (1996) Phase II study of dual I-131-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 2:1811\u20131818","journal-title":"Clin Cancer Res"},{"key":"477_CR98","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/cbr.1997.12.305","volume":"12","author":"D SlavinChiorini","year":"1997","unstructured":"SlavinChiorini D, Kashmiri S, Lee H, Milenic D, Poole D, Bernon E et al (1997) A CDR-grafted (humanized) domain-deleted antitumour antibody. Cancer Biother Radiopharm 12:305\u2013316. https:\/\/doi.org\/10.1089\/cbr.1997.12.305","journal-title":"Cancer Biother Radiopharm"},{"key":"477_CR99","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/cbr.2006.21.106","volume":"21","author":"P Chinn","year":"2006","unstructured":"Chinn P, Morena R, Santoro D, Kazules T, Kashmiri S, Schlom J et al (2006) Pharmacokinetics and ibmor localization of In-111-labeled HuCC49 Delta C(H)2 in BALB\/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm 21:106\u2013116. https:\/\/doi.org\/10.1089\/cbr.2006.21.106","journal-title":"Cancer Biother Radiopharm"},{"key":"477_CR100","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1073\/pnas.87.15.5702","volume":"87","author":"B Mueller","year":"1990","unstructured":"Mueller B, Reisfeld R, Gillies S (1990) serum half-life and tumour-localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside-GD2. Proc Natl Acad Sci USA 87:5702\u20135705. https:\/\/doi.org\/10.1073\/pnas.87.15.5702","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR101","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ijc.2910530119","volume":"53","author":"D Slavinchiorini","year":"1993","unstructured":"Slavinchiorini D, Hand P, Kashmiri S, Calvo B, Zaremba S, Schlom J (1993) Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 53:97\u2013103. https:\/\/doi.org\/10.1002\/ijc.2910530119","journal-title":"Int J Cancer"},{"key":"477_CR102","first-page":"5957","volume":"55","author":"D Slavinchiorini","year":"1995","unstructured":"Slavinchiorini D, Kashmiri S, Schlom J, Calvo B, Shu L, Schott M et al (1995) Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 55:5957\u201367","journal-title":"Cancer Res"},{"key":"477_CR103","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1073\/pnas.94.2.469","volume":"94","author":"J Heath","year":"1997","unstructured":"Heath J, White S, Johnstone C, Catimel B, Simpson R, Moritz R et al (1997) The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 94:469\u2013474. https:\/\/doi.org\/10.1073\/pnas.94.2.469","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR104","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1006\/bbrc.1997.6966","volume":"236","author":"G Ritter","year":"1997","unstructured":"Ritter G, Cohen L, Nice E, Catimel B, Burgess A, Moritz R et al (1997) Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem Biophys Res Commun 236:682\u2013686. https:\/\/doi.org\/10.1006\/bbrc.1997.6966","journal-title":"Biochem Biophys Res Commun"},{"key":"477_CR105","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1200\/JCO.1990.8.11.1894","volume":"8","author":"S Welt","year":"1990","unstructured":"Welt S, Divgi C, Real F, Yeh S, Garinchesa P, Finstad C et al (1990) quantitative-analysis of antibody localization in human metastatic colon cancer\u2014a phase-I study of monoclonal antibody-A33. J Clin Oncol 8:1894\u20131906. https:\/\/doi.org\/10.1200\/JCO.1990.8.11.1894","journal-title":"J Clin Oncol"},{"key":"477_CR106","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.1994.12.8.1561","volume":"12","author":"S Welt","year":"1994","unstructured":"Welt S, DivgI C, Kemeny N, Finn R, Scott A, Graham M et al (1994) Phase I\/II study of iodine 131-LABELED monoclonal-antibody A33 in patients with advanced colon-canceR. J Clin Oncol 12:1561\u20131571. https:\/\/doi.org\/10.1200\/JCO.1994.12.8.1561","journal-title":"J Clin Oncol"},{"key":"477_CR107","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/bjc.1995.516","volume":"72","author":"D King","year":"1995","unstructured":"King D, Antoniw P, Owens R, Adair J, Haines A, Farnsworth A et al (1995) Preparation and preclinical evaluation of humanized A33 immunoconjugates for radioimmunotherapy. Br J Cancer 72:1364\u201372. https:\/\/doi.org\/10.1038\/bjc.1995.516","journal-title":"Br J Cancer"},{"key":"477_CR108","first-page":"1338","volume":"9","author":"S Welt","year":"2003","unstructured":"Welt S, Ritter G, Williams C, Cohen L, John M, Jungbluth A et al (2003) Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 9:1338\u20131346","journal-title":"Clin Cancer Res"},{"key":"477_CR109","first-page":"1347","volume":"9","author":"S Welt","year":"2003","unstructured":"Welt S, Ritter G, Williams C, Cohen L, Jungbluth A, Richards E et al (2003) Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 9:1347\u20131353","journal-title":"Clin Cancer Res"},{"key":"477_CR110","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1158\/1078-0432.CCR-04-2329","volume":"11","author":"A Scott","year":"2005","unstructured":"Scott A, Lee F, Jones R, Hopkins W, MacGregor D, Cebon J et al (2005) A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumour uptake. Clin Cancer Res 11:4810\u20134817. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2329","journal-title":"Clin Cancer Res"},{"key":"477_CR111","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1158\/1078-0432.CCR-04-2330","volume":"11","author":"G Chong","year":"2005","unstructured":"Chong G, Lee F, Hopkins W, Tebbutt N, Cebon J, Mountain A et al (2005) Phase I trial of I-131-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 11:4818\u20134826. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2330","journal-title":"Clin Cancer Res"},{"key":"477_CR112","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/BF01542654","volume":"5","author":"H Koprowski","year":"1979","unstructured":"Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P (1979) colorectal-carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 5:957\u2013972. https:\/\/doi.org\/10.1007\/BF01542654","journal-title":"Somatic Cell Genetics"},{"key":"477_CR113","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1073\/pnas.76.3.1438","volume":"76","author":"M Herlyn","year":"1979","unstructured":"Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen\u2014detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76:1438\u20131442. https:\/\/doi.org\/10.1073\/pnas.76.3.1438","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR114","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2353\/ajpath.2007.070152","volume":"171","author":"M Trzpis","year":"2007","unstructured":"Trzpis M, McLaughlin P, de Leij L, Harmsen M (2007) Epithelial cell adhesion molecule\u2014more than a carcinoma marker and adhesion molecule. Am J Pathol 171:386\u2013395. https:\/\/doi.org\/10.2353\/ajpath.2007.070152","journal-title":"Am J Pathol"},{"key":"477_CR115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ijc.2910380109","volume":"38","author":"H Gottlinger","year":"1986","unstructured":"Gottlinger H, Funke I, Johnson J, Gokel J, Riethmuller G (1986) The epithelial-cell surface-antigen 17\u20131A, a target for antibody-mediated tumour-therapy\u2014its biochemical nature, tissue distribution and recognition by different monoclonal-antibodies. Int J Cancer 38:47\u201353","journal-title":"Int J Cancer"},{"key":"477_CR116","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1073\/pnas.84.1.214","volume":"84","author":"L Sun","year":"1987","unstructured":"Sun L, Curtis P, Rakowiczszulczynska E, Ghrayeb J, Chang N, Morrison S et al (1987) chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17\u20131A. Proc Natl Acad Sci USA 84:214\u2013218. https:\/\/doi.org\/10.1073\/pnas.84.1.214","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR117","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.4049\/jimmunol.138.12.4534","volume":"138","author":"D Shaw","year":"1987","unstructured":"Shaw D, Khazaeli M, Sun L, Ghrayeb J, Daddona P, Mckinney S et al (1987) Characterization of a mouse human chimeric monoclonal-antibody (17\u20131A) to a colon cancer tumour-associated antigen. J Immunol 138:4534\u20134538","journal-title":"J Immunol"},{"key":"477_CR118","first-page":"1547","volume":"3","author":"D Macey","year":"1997","unstructured":"Macey D, Grant E, Kasi L, Rosenblum M, Zhang H, Katz R et al (1997) Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of I-131-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res 3:1547\u20131555","journal-title":"Clin Cancer Res"},{"key":"477_CR119","first-page":"S5925","volume":"55","author":"J Murray","year":"1995","unstructured":"Murray J, Macey D, Grant E, Rosenblum M, Kasi L, Zhang H et al (1995) Enhanced tag-72 expression and turner uptake of radiolabeled monoclonal-antibody CC49 In metastatic breast-cancer patients following alpha-interferon treatment. Can Res 55:S5925\u2013S5928","journal-title":"Can Res"},{"key":"477_CR120","first-page":"1447","volume":"1","author":"T Mulligan","year":"1995","unstructured":"Mulligan T, Carrasquillo J, Chung Y, Milenic D, Schlom J, Feuerstein I et al (1995) Phase I study of intravenous Lu-177-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1:1447\u20131454","journal-title":"Clin Cancer Res"},{"key":"477_CR121","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1073\/pnas.89.8.3503","volume":"89","author":"J Marken","year":"1992","unstructured":"Marken J, Schieven G, Hellstrom I, Hellstrom K, Aruffo A (1992) Cloning and expression of the tumour-associated antigen-L6. Proc Natl Acad Sci USA 89:3503\u20133507. https:\/\/doi.org\/10.1073\/pnas.89.8.3503","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR122","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1200\/JCO.1990.8.6.1083","volume":"8","author":"G Goodman","year":"1990","unstructured":"Goodman G, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D et al (1990) Phase-I trial of murine monoclonal antibody-L6 in breast, colon, ovarian, and lung-cancer. J Clin Oncol 8:1083\u20131092. https:\/\/doi.org\/10.1200\/JCO.1990.8.6.1083","journal-title":"J Clin Oncol"},{"key":"477_CR123","first-page":"2357","volume":"55","author":"H Svensson","year":"1995","unstructured":"Svensson H, Vrudhula V, Emswiler J, Macmaster J, CosanD W, Senter P et al (1995) In-vitro and in-vivo activities of a doxorubicin prodrug in combination with monoclonal-antibody beta-lactamase conjugates. Can Res 55:2357\u20132365","journal-title":"Can Res"},{"key":"477_CR124","first-page":"1745","volume":"17","author":"S DeNardo","year":"1997","unstructured":"DeNardo S, OGrady L, Richman C, Goldstein D, ODonnell R, DeNardo D et al (1997) Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 17:1745\u201351","journal-title":"Anticancer Res"},{"key":"477_CR125","first-page":"1735","volume":"17","author":"S DeNardo","year":"1997","unstructured":"DeNardo S, Richman C, Goldstein D, Shen S, Salako Q, Kukis D et al (1997) Yttrium-90\/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 17:1735\u20131744","journal-title":"Anticancer Res"},{"key":"477_CR126","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05094-1","author":"B Altunay","year":"2020","unstructured":"Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong N, Ting H et al (2020) HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-020-05094-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"477_CR127","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2967\/jnumed.112.111021","volume":"54","author":"C Xavier","year":"2013","unstructured":"Xavier C, Vaneycken I, Dhuyvetter M, Heemskerk J, Keyaerts M, Vincke C et al (2013) Synthesis, preclinical validation, dosimetry, and toxicity of Ga-68-NOTA-Anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med 54:776\u201384. https:\/\/doi.org\/10.2967\/jnumed.112.111021","journal-title":"J Nucl Med"},{"key":"477_CR128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C et al (2016) Phase I study of Ga-68-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 57:27\u201333. https:\/\/doi.org\/10.2967\/jnumed.115.162024","journal-title":"J Nucl Med"},{"key":"477_CR129","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","volume":"23","author":"M D'Huyvetter","year":"2017","unstructured":"D\u2019Huyvetter M, De Vos J, Xavier C, Pruszynski M, Sterckx Y, Massa S et al (2017) I-131-labeled Anti-HER2 camelid sdAb as a theranostic tool in cancer treatment. Clin Cancer Res 23:6616\u20136628. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0310","journal-title":"Clin Cancer Res"},{"key":"477_CR130","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"E Perez","year":"2014","unstructured":"Perez E, Romond E, Suman V, Jeong J, Sledge G, Geyer C et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744. https:\/\/doi.org\/10.1200\/JCO.2014.55.5730","journal-title":"J Clin Oncol"},{"key":"477_CR131","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jlcr.3465","volume":"60","author":"M Kameswaran","year":"2017","unstructured":"Kameswaran M, Gota V, Ambade R, Gupta S, Dash A (2017) Preparation and preclinical evaluation of I-131-trastuzumab for breast cancer. J Labelled Compd Radiopharm 60:12\u201319. https:\/\/doi.org\/10.1002\/jlcr.3465","journal-title":"J Labelled Compd Radiopharm"},{"key":"477_CR132","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/jama.250.5.630","volume":"250","author":"D Goldenberg","year":"1983","unstructured":"Goldenberg D, Deland F, Bennett S, Primus F, Nelson M, Flanigan R et al (1983) Radioimmunodetection of prostatic-cancer\u2014invivo use of radioactive antibodies against prostatic acid-phosphatase for diagnosis and detection of prostatic-cancer by nuclear imaging. JAMA J Am Med Assoc 250:630\u2013635. https:\/\/doi.org\/10.1001\/jama.250.5.630","journal-title":"JAMA J Am Med Assoc"},{"key":"477_CR133","first-page":"3254S","volume":"5","author":"R Meredith","year":"1999","unstructured":"Meredith R, Khazaeli M, Macey D, Grizzle W, Mayo M, Schlom J et al (1999) Phase II study of interferon-enhanced I-131-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 5:3254S-S3258","journal-title":"Clin Cancer Res"},{"key":"477_CR134","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","volume":"46","author":"K Bouchelouche","year":"2016","unstructured":"Bouchelouche K, Turkbey B, Choyke P (2016) PSMA PET and radionuclide therapy in prostate cancer. Semin Nucl Med 46:522\u2013535. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.006","journal-title":"Semin Nucl Med"},{"key":"477_CR135","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","volume":"22","author":"U Haberkorn","year":"2016","unstructured":"Haberkorn U, Eder M, Kopka K, Babich J, Eisenhut M (2016) New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res 22:9\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0820","journal-title":"Clin Cancer Res"},{"key":"477_CR136","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/cncr.24795","volume":"116","author":"S Tagawa","year":"2010","unstructured":"Tagawa S, Beltran H, Vallabhajosula S, Goldsmith S, Osborne J, Matulich D et al (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116:1075\u20131083. https:\/\/doi.org\/10.1002\/cncr.24795","journal-title":"Cancer"},{"key":"477_CR137","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"M Sadaghiani","year":"2021","unstructured":"Sadaghiani M, Sheikhbahaei S, Werner R, Pienta K, Pomper M, Solnes L et al (2021) A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol 80:82\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.004","journal-title":"Eur Urol"},{"key":"477_CR138","doi-asserted-by":"crossref","unstructured":"Morris M, De Bono J, Chi K, Fizazi K, Herrmann K (2021) Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4"},{"key":"477_CR139","unstructured":"Novartis. Novartis receives FDA breakthrough therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). https:\/\/www.novartis.com\/news\/novartis-receives-fda-breakthrough-therapy-designation-investigational-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc. Accessed 27 Nov 2021"},{"key":"477_CR140","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-540-71279-4_10","volume":"177","author":"R Wilkowski","year":"2008","unstructured":"Wilkowski R, Wolf M, Heinemann V (2008) Primary advanced unresectable pancreatic cancer. Recent Results Cancer Res 177:79\u201393","journal-title":"Recent Results Cancer Res"},{"key":"477_CR141","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/sj.bjc.6602232","volume":"91","author":"C Qu","year":"2004","unstructured":"Qu C, Li Y, Song Y, Rizvi S, Raja C, Zhang D et al (2004) MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by Bi-213-C595 radioimmunoconjugate. Br J Cancer 91:2086\u20132093. https:\/\/doi.org\/10.1038\/sj.bjc.6602232","journal-title":"Br J Cancer"},{"key":"477_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040157","author":"J Winter","year":"2012","unstructured":"Winter J, Tang L, Klimstra D, Brennan M, Brody J, Rocha F et al (2012) A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0040157","journal-title":"PLoS ONE"},{"key":"477_CR143","first-page":"1105","volume":"55","author":"D Gold","year":"1995","unstructured":"Gold D, Alisauskas R, Sharkey R (1995) Targeting of xenografted pancreatic-cancer with a new monoclonal-antibodY, PAM4. Can Res 55:1105\u20131110","journal-title":"Can Res"},{"key":"477_CR144","first-page":"S5911","volume":"55","author":"G Mariani","year":"1995","unstructured":"Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D et al (1995) Initial turner targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal-antibody PAM4 in patients with pancreatic-cancer. Cancer Res 55:S5911\u2013S5","journal-title":"Cancer Res"},{"key":"477_CR145","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<660::AID-IJC24>3.0.CO;2-E","volume":"71","author":"D Gold","year":"1997","unstructured":"Gold D, Cardillo T, Vardi Y, Blumenthal R (1997) Radioimmunotherapy of experimental pancreatic cancer with I-131-labeled monoclonal antibody PAM4. Int J Cancer 71:660\u2013667","journal-title":"Int J Cancer"},{"key":"477_CR146","first-page":"3186","volume":"7","author":"T Cardillo","year":"2001","unstructured":"Cardillo T, Ying Z, Gold D (2001) Therapeutic advantage of (90)Yttrium-versus (131)Iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 7:3186\u20133192","journal-title":"Clin Cancer Res"},{"key":"477_CR147","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"H El-Serag","year":"2007","unstructured":"El-Serag H, Rudolph L (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557\u20132576. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.061","journal-title":"Gastroenterology"},{"key":"477_CR148","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/S1590-8658(10)60507-5","volume":"42","author":"H Nordenstedt","year":"2010","unstructured":"Nordenstedt H, White D, El-Serag H (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42:S206\u2013S214. https:\/\/doi.org\/10.1016\/S1590-8658(10)60507-5","journal-title":"Dig Liver Dis"},{"key":"477_CR149","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1158\/1078-0432.CCR-10-0681","volume":"16","author":"R Finn","year":"2010","unstructured":"Finn R (2010) Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? (vol 16, pg 390, 2010). Clin Cancer Res 16:2696. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0681","journal-title":"Clin Cancer Res"},{"key":"477_CR150","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1200\/JCO.1985.3.12.1573","volume":"3","author":"S Order","year":"1985","unstructured":"Order S, Stillwagon G, Klein J, Leichner P, Siegelman S, Fishman E et al (1985) I-131 antiferritin, a new treatment modality in hepatoma\u2014a radiation-therapy-oncology-group study. J Clin Oncol 3:1573\u20131582. https:\/\/doi.org\/10.1200\/JCO.1985.3.12.1573","journal-title":"J Clin Oncol"},{"key":"477_CR151","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0140-6736(83)92220-1","volume":"1","author":"Y Liu","year":"1983","unstructured":"Liu Y, Yang K, Wu Y, Gang Y, Zhu D (1983) Treatment of advanced primary hepatocellular-carcinoma by I-131-labeled-anti-AFP. Lancet 1:531\u2013532","journal-title":"Lancet"},{"key":"477_CR152","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00000658-199302000-00009","volume":"217","author":"J Sitzmann","year":"1993","unstructured":"Sitzmann J, Abrams R (1993) Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 217:149\u2013154. https:\/\/doi.org\/10.1097\/00000658-199302000-00009","journal-title":"Ann Surg"},{"key":"477_CR153","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/1084978042484777","volume":"19","author":"S Chen","year":"2004","unstructured":"Chen S, Li B, Xie H, Xu L, Niu G, Fan K et al (2004) Phase I clinical trial of targeted therapy using I-131-hepama-1 mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm 19:589\u2013600","journal-title":"Cancer Biother Radiopharm"},{"key":"477_CR154","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.cej.0000236245.40619.c3","volume":"16","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Zhou J, Ku X, Chen X, Zhang L, Xu J et al (2007) Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 16:196\u2013202. https:\/\/doi.org\/10.1097\/01.cej.0000236245.40619.c3","journal-title":"Eur J Cancer Prev"},{"key":"477_CR155","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijrobp.2005.12.034","volume":"65","author":"Z Chen","year":"2006","unstructured":"Chen Z, Mi L, Xu J, Song F, Zhang Q, Zhang Z et al (2006) Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (I-131) metuximab injection: clinical phase I\/II trials. Int J Radiat Oncol Biol Phys 65:435\u2013444. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.12.034","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"477_CR156","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4161\/cbt.5.3.2431","volume":"5","author":"Z Zhang","year":"2006","unstructured":"Zhang Z, Bian H, Feng Q, Mi L, Mo T, Kuang A et al (2006) Biodistribution and localization of Iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 5:318\u2013322. https:\/\/doi.org\/10.4161\/cbt.5.3.2431","journal-title":"Cancer Biol Ther"},{"key":"477_CR157","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s00259-012-2145-5","volume":"39","author":"L Wu","year":"2012","unstructured":"Wu L, Yang Y, Ge N, Shen S, Liang J, Wang Y et al (2012) Hepatic artery injection of I-131-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur J Nucl Med Mol Imaging 39:1306\u20131315. https:\/\/doi.org\/10.1007\/s00259-012-2145-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"477_CR158","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.3748\/wjg.v19.i47.9104","volume":"19","author":"Q He","year":"2013","unstructured":"He Q, Lu W, Liu Y, Guan Y, Kuang A (2013) I-131-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 19:9104\u20139110. https:\/\/doi.org\/10.3748\/wjg.v19.i47.9104","journal-title":"World J Gastroenterol"},{"key":"477_CR159","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hep.21465","volume":"45","author":"J Xu","year":"2007","unstructured":"Xu J, Shen Z, Chen X, Zhang Q, Bian H, Zhu P et al (2007) A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45:269\u2013276. https:\/\/doi.org\/10.1002\/hep.21465","journal-title":"Hepatology"},{"key":"477_CR160","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju239","author":"H Bian","year":"2014","unstructured":"Bian H, Zheng J, Nan G, Li R, Chen C, Hu C et al (2014) Randomized trial of [I-131] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation. JNCI J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju239","journal-title":"JNCI J Natl Cancer Inst"},{"key":"477_CR161","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S2468-1253(19)30422-4","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y et al (2020) Adjuvant I-131-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 5:548\u2013560. https:\/\/doi.org\/10.1016\/S2468-1253(19)30422-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"477_CR162","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/jcp.2010.085142","volume":"64","author":"J Huang","year":"2011","unstructured":"Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z et al (2011) Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol 64:343\u2013348. https:\/\/doi.org\/10.1136\/jcp.2010.085142","journal-title":"J Clin Pathol"},{"key":"477_CR163","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00253-011-3335-y","volume":"91","author":"J Huang","year":"2011","unstructured":"Huang J, Liang J, Tang Q, Wang Z, Chen L, Zhu J et al (2011) An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumours. Appl Microbiol Biotechnol 91:1341\u20131351. https:\/\/doi.org\/10.1007\/s00253-011-3335-y","journal-title":"Appl Microbiol Biotechnol"},{"key":"477_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/srep10660","author":"J Huang","year":"2015","unstructured":"Huang J, Tang Q, Wang C, Yu H, Feng Z, Zhu J (2015) Molecularly targeted therapy of human hepatocellular carcinoma xenografts with radio-iodinated anti-VEGFR2 murine-human chimeric fab. Sci Rep. https:\/\/doi.org\/10.1038\/srep10660","journal-title":"Sci Rep"},{"key":"477_CR165","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cancergen.2012.10.009","volume":"205","author":"M Goodenberger","year":"2012","unstructured":"Goodenberger M, Jenkins R (2012) Genetics of adult glioma. Cancer Genet 205:613\u2013621. https:\/\/doi.org\/10.1016\/j.cancergen.2012.10.009","journal-title":"Cancer Genet"},{"key":"477_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00963","author":"O Taylor","year":"2019","unstructured":"Taylor O, Brzozowski J, Skelding K (2019) Glioblastoma multiforme: an overview of emerging therapeutic targets. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00963","journal-title":"Front Oncol"},{"key":"477_CR167","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8","volume":"48","author":"S Zimm","year":"1981","unstructured":"Zimm S, Wampler G, Stablein D, Hazra T, Young H (1981) Intra-cerebral metastases in solid-tumour patients\u2014natural-history and results of treatment. Cancer 48:384\u2013394. https:\/\/doi.org\/10.1002\/1097-0142(19810715)48:2%3c384::AID-CNCR2820480227%3e3.0.CO;2-8","journal-title":"Cancer"},{"key":"477_CR168","first-page":"A49","volume":"58","author":"L Schouten","year":"2002","unstructured":"Schouten L, Rutten J, Huveneers H, Twijnstra A (2002) Incidence of brain Metastases in a cohort of patients with breast, colon, kidney, and lung cancer, and melanoma. Neurology 58:A49","journal-title":"Neurology"},{"key":"477_CR169","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.ctrv.2014.05.007","volume":"40","author":"G Lombardi","year":"2014","unstructured":"Lombardi G, Di Stefano A, Farina P, Zagonel V, Tabouret E (2014) Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev 40:951\u2013959. https:\/\/doi.org\/10.1016\/j.ctrv.2014.05.007","journal-title":"Cancer Treat Rev"},{"key":"477_CR170","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1212\/01.CON.0000413659.12304.a6","volume":"18","author":"C Lu-Emerson","year":"2012","unstructured":"Lu-Emerson C, Eichler AF (2012) Brain metastases. Continuum Lifelong Learn Neurol 18:295\u2013311","journal-title":"Continuum Lifelong Learn Neurol"},{"key":"477_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00019606-200403000-00001","volume":"13","author":"A Marquez","year":"2004","unstructured":"Marquez A, Wu R, Zhao J, Tao J, Shi Z (2004) Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH (TM)) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13:1\u20138. https:\/\/doi.org\/10.1097\/00019606-200403000-00001","journal-title":"Diagn Mol Pathol"},{"key":"477_CR172","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0003-9861(87)90062-2","volume":"252","author":"U Murthy","year":"1987","unstructured":"Murthy U, Basu A, Rodeck U, Herlyn M, Ross A, Das M (1987) Binding of an antagonistic monoclonal-antibody to an intact and fragmented egf-receptor polypeptide. Arch Biochem Biophys 252:549\u2013560. https:\/\/doi.org\/10.1016\/0003-9861(87)90062-2","journal-title":"Arch Biochem Biophys"},{"key":"477_CR173","first-page":"243","volume":"34","author":"LW Brady","year":"1990","unstructured":"Brady LW, Markoe AM, Woo DV et al (1990) Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas: a pilot study. J Neurosurg Sci 34:243\u20139","journal-title":"J Neurosurg Sci"},{"key":"477_CR174","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0360-3016(92)91009-C","volume":"22","author":"L Brady","year":"1992","unstructured":"Brady L, Miyamoto C, Woo D, Rackover M, Emrich J, Bender H et al (1992) Malignant astrocytomas treated with I-125 labeled monoclonal-antibody 425 against epidermal growth-factor receptor\u2014a phase II trial. Int J Radiat Oncol Biol Phys 22:225\u2013230. https:\/\/doi.org\/10.1016\/0360-3016(92)91009-C","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"477_CR175","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00000421-200212000-00001","volume":"25","author":"J Emrich","year":"2002","unstructured":"Emrich J, Brady L, Quang T, Class R, Miyamoto C, Black P et al (2002) Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients\u2014ten-year synopsis of a novel treatment. Am J Clin Oncol Cancer Clin Trials 25:541\u2013546. https:\/\/doi.org\/10.1097\/00000421-200212000-00001","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"477_CR176","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","volume":"113","author":"L Li","year":"2010","unstructured":"Li L, Quang T, Gracely E, Kim J, Emrich J, Yaeger T et al (2010) A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme Clinical article. J Neurosurg 113:192\u2013198. https:\/\/doi.org\/10.3171\/2010.2.JNS091211","journal-title":"J Neurosurg"},{"key":"477_CR177","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","volume":"37","author":"Z An","year":"2018","unstructured":"An Z, Aksoy O, Zheng T, Fan Q, Weiss W (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561\u20131575. https:\/\/doi.org\/10.1038\/s41388-017-0045-7","journal-title":"Oncogene"},{"key":"477_CR178","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1073\/pnas.232686499","volume":"100","author":"A Jungbluth","year":"2003","unstructured":"Jungbluth A, Stockert E, Huang H, Collins V, Coplan K, Iversen K et al (2003) A monoclonal antibody recognizing human cancers with amplification\/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100:639\u2013644. https:\/\/doi.org\/10.1073\/pnas.232686499","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR179","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1593\/neo.07721","volume":"9","author":"R Perera","year":"2007","unstructured":"Perera R, Zoncu R, Johns T, Pypaert M, Lee F, Mellman I et al (2007) Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia 9:1099\u20131110. https:\/\/doi.org\/10.1593\/neo.07721","journal-title":"Neoplasia"},{"key":"477_CR180","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.nucmedbio.2008.11.001","volume":"36","author":"M Hens","year":"2009","unstructured":"Hens M, Vaidyanathan G, Welsh P, Zalutsky M (2009) Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with Lu-177: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 36:117\u2013128. https:\/\/doi.org\/10.1016\/j.nucmedbio.2008.11.001","journal-title":"Nucl Med Biol"},{"key":"477_CR181","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.nucmedbio.2010.04.020","volume":"37","author":"M Hens","year":"2010","unstructured":"Hens M, Vaidyanathan G, Zhao X, Bigner D, Zalutsky M (2010) Anti-EGFRvIII monoclonal antibody armed with Lu-177: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 37:741\u2013750. https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.04.020","journal-title":"Nucl Med Biol"},{"key":"477_CR182","first-page":"2807","volume":"49","author":"M Zalutsky","year":"1989","unstructured":"Zalutsky M, Moseley R, Coakham H, Coleman R, Bigner D (1989) Pharmacokinetics and tumour-localization of I-131-Labeled anti-tenascin monoclonal antibody-81C6 In patients with gliomas and other intracranial malignancies. Can Res 49:2807\u20132813","journal-title":"Can Res"},{"key":"477_CR183","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0165-5728(92)90029-K","volume":"36","author":"J Ventimiglia","year":"1992","unstructured":"Ventimiglia J, Wikstrand C, Ostrowski L, Bourdon M, Lightner V, Bigner D (1992) Tenascin expression in human glioma cell-lines and normal-tissues. J Neuroimmunol 36:41\u201355. https:\/\/doi.org\/10.1016\/0165-5728(92)90029-K","journal-title":"J Neuroimmunol"},{"key":"477_CR184","first-page":"2796","volume":"43","author":"M Bourdon","year":"1983","unstructured":"Bourdon M, Wikstrand C, Furthmayr H, Matthews T, Bigner D (1983) Human glioma-mesenchymal extracellular-matrix antigen defined by monoclonal-antibody. Can Res 43:2796\u20132805","journal-title":"Can Res"},{"key":"477_CR185","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/nar\/19.3.525","volume":"19","author":"A Siri","year":"1991","unstructured":"Siri A, Carnemolla B, Saginati M, Leprini A, Casari G, Baralle F et al (1991) Human tenascin\u2014primary structure, pre-messenger-rna splicing patterns and localization of the epitopes recognized by 2 monoclonal-antibodies. Nucleic Acids Res 19:525\u2013531. https:\/\/doi.org\/10.1093\/nar\/19.3.525","journal-title":"Nucleic Acids Res"},{"key":"477_CR186","first-page":"912","volume":"47","author":"D Reardon","year":"2006","unstructured":"Reardon D, Quinn J, Akabani G, Coleman R, Friedman A, Friedman H et al (2006) Novel human IgG2b\/murine chimeric antitenascin monoclonal antibody construct radiolabeled with I-131 and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 47:912\u2013918","journal-title":"J Nucl Med"},{"key":"477_CR187","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ijc.2910510103","volume":"51","author":"P Riva","year":"1992","unstructured":"Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M et al (1992) Treatment of intracranial human glioblastoma by direct intratumoural administration of I-131-Labeled anti-tenascin monoclonal-antibody BC-2. Int J Cancer 51:7\u201313. https:\/\/doi.org\/10.1002\/ijc.2910510103","journal-title":"Int J Cancer"},{"key":"477_CR188","doi-asserted-by":"crossref","unstructured":"Riva P, Arista A, Sturiale C, Tlson V, Lazzari S et al (1994) Glioblastoma therapy by direct intralesional administration of i-131 radioiodine labeled antitenascin antibodies. Cell Biophys 24\/25","DOI":"10.1007\/BF02789213"},{"key":"477_CR189","first-page":"5952","volume":"55","author":"P Riva","year":"1995","unstructured":"Riva P, Arista A, Franceschi G, Frattarelli M, SturialE C, Riva N et al (1995) Local treatment of malignant gliomas by direct infusion of specific monoclonal-antibodies labeled with I-131\u2014comparison of the results obtained in recurrent and newly-diagnosed tumours. Cancer Res 55:5952\u20136","journal-title":"Cancer Res"},{"key":"477_CR190","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/028418699431438","volume":"38","author":"P Riva","year":"1999","unstructured":"Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini A et al (1999) I-131 radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma\u2014Phase I and II study. Acta Oncol 38:351\u2013359","journal-title":"Acta Oncol"},{"key":"477_CR191","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/jcb.240280302","volume":"28","author":"M Bourdon","year":"1985","unstructured":"Bourdon M, Matthews T, Pizzo S, Bigner D (1985) Immunochemical and biochemical-characterization of a glioma-associated extracellular-matrix glycoprotein. J Cell Biochem 28:183\u2013195. https:\/\/doi.org\/10.1002\/jcb.240280302","journal-title":"J Cell Biochem"},{"key":"477_CR192","first-page":"133","volume":"4","author":"M Bourdon","year":"1984","unstructured":"Bourdon M, Coleman R, Blasberg R, Groothuis D, Bigner D (1984) Monoclonal-antibody localization in subcutaneous and intracranial human glioma xenografts - paired-label and imaging analysis. Anticancer Res 4:133\u2013140","journal-title":"Anticancer Res"},{"key":"477_CR193","first-page":"1941","volume":"47","author":"Y Lee","year":"1987","unstructured":"Lee Y, Bullard D, Wikstrand C, Zalutsky M, Muhlbaier L, Bigner D (1987) Comparison of monoclonal-antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Can Res 47:1941\u20131946","journal-title":"Can Res"},{"key":"477_CR194","first-page":"559","volume":"48","author":"Y Lee","year":"1988","unstructured":"Lee Y, Bullard D, Zalutsky M, Coleman R, Wikstrand C, Friedman H et al (1988) Therapeutic efficacy of antiglioma mesenchymal extracellular-matrix I-131-radiolabeled murine monoclonal-antibody in a human glioma xenograft model. Can Res 48:559\u2013566","journal-title":"Can Res"},{"key":"477_CR195","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/00004424-199306000-00003","volume":"28","author":"S Schold","year":"1993","unstructured":"Schold S, Zalutsky M, Coleman R, Glantz M, Friedman A, Jaszczak R et al (1993) distribution and dosimetry of I-123 labeled monoclonal antibody-81C6 in patients with anaplastic glioma. Invest Radiol 28:488\u2013496","journal-title":"Invest Radiol"},{"key":"477_CR196","first-page":"4105","volume":"50","author":"M Zalutsky","year":"1990","unstructured":"Zalutsky M, Moseley R, Benjamin J, Colapinto E, Fuller G, Coakham H et al (1990) Monoclonal-antibody and F(ab\u2019)2 fragment delivery to tumour in patients with glioma\u2014comparison of intracarotid and intravenous administration. Can Res 50:4105\u20134110","journal-title":"Can Res"},{"key":"477_CR197","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0360-3016(99)00500-3","volume":"46","author":"G Akabani","year":"2000","unstructured":"Akabani G, Cokgor I, Coleman R, Trotter D, Wong T, Friedman H et al (2000) Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46:947\u2013958. https:\/\/doi.org\/10.1016\/S0360-3016(99)00500-3","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"477_CR198","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1200\/JCO.2000.18.22.3862","volume":"18","author":"I Cokgor","year":"2000","unstructured":"Cokgor I, Akabani G, Kuan C, Friedman H, Friedman A, Coleman R et al (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862\u20133872. https:\/\/doi.org\/10.1200\/JCO.2000.18.22.3862","journal-title":"J Clin Oncol"},{"key":"477_CR199","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1200\/JCO.1998.16.6.2202","volume":"16","author":"D Bigner","year":"1998","unstructured":"Bigner D, Brown M, Friedman A, Coleman R, Akabani G, Friedman H et al (1998) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16:2202\u20132212. https:\/\/doi.org\/10.1200\/JCO.1998.16.6.2202","journal-title":"J Clin Oncol"},{"key":"477_CR200","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.20.5.1389","volume":"20","author":"D Reardon","year":"2002","unstructured":"Reardon D, Akabani G, Coleman R, Friedman A, Friedman H, Herndon J et al (2002) Phase II trial of murine I-131-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389\u20131397. https:\/\/doi.org\/10.1200\/JCO.20.5.1389","journal-title":"J Clin Oncol"},{"key":"477_CR201","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0165-5728(94)90106-6","volume":"52","author":"X He","year":"1994","unstructured":"He X, Archer G, Wikstrand C, Morrison S, Zalutsky M, Bigner D et al (1994) Generation and characterization of a mouse\/human chimeric antibody-directed against extracellular-matrix protein tenascin. J Neuroimmunol 52:127\u2013137. https:\/\/doi.org\/10.1016\/0165-5728(94)90106-6","journal-title":"J Neuroimmunol"},{"key":"477_CR202","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-05-2804","volume":"12","author":"S Brack","year":"2006","unstructured":"Brack S, Silacci M, Birchler M, Neri D (2006) Tumour-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12:3200\u20133208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2804","journal-title":"Clin Cancer Res"},{"key":"477_CR203","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.amsu.2014.06.014","volume":"3","author":"EP Weledji","year":"2014","unstructured":"Weledji EP, Assob JC (2014) The ubiquitous neural cell adhesion molecule (N-CAM). Ann Med Surg 3:77\u201381","journal-title":"Ann Med Surg"},{"key":"477_CR204","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/bjc.1993.25","volume":"67","author":"V Papanastassiou","year":"1993","unstructured":"Papanastassiou V, Pizer B, Coakham H, Bullimore J, Zananiri T, Kemshead J (1993) Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of I-131 monoclonal-antibody\u2014feasibility, pharmacokinetics and dosimetry. Br J Cancer 67:144\u2013151. https:\/\/doi.org\/10.1038\/bjc.1993.25","journal-title":"Br J Cancer"},{"key":"477_CR205","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0022-3476(84)80122-5","volume":"105","author":"A Goldman","year":"1984","unstructured":"Goldman A, Vivian G, Gordon I, Pritchard J, Kemshead J (1984) Immunolocalization of neuroblastoma using radiolabeled monoclonal antibody UJ13A. J Pediatr 105:252\u2013256","journal-title":"J Pediatr"},{"key":"477_CR206","unstructured":"Jones D, Lashford L, Dicks-Mireaux C, Kemshead J (1987) Comparison of pharmacokinetics of radiolabeled monoclonal antibody UJ13A in patients and animal models NCI monographs. J Natl Cancer Inst 125\u201330"},{"key":"477_CR207","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrc1627","volume":"5","author":"D Neri","year":"2005","unstructured":"Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5:436\u2013446. https:\/\/doi.org\/10.1038\/nrc1627","journal-title":"Nat Rev Cancer"},{"key":"477_CR208","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cmdc.200600181","volume":"2","author":"J Rybak","year":"2007","unstructured":"Rybak J, Trachsel E, Scheuermann J, Neri D (2007) Ligand-based vascular targeting of disease. ChemMedChem 2:22\u201340. https:\/\/doi.org\/10.1002\/cmdc.200600181","journal-title":"ChemMedChem"},{"key":"477_CR209","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1083\/jcb.108.3.1139","volume":"108","author":"B Carnemolla","year":"1989","unstructured":"Carnemolla B, Balza E, Siri A, Zardi L, Nicotra M, Bigotti A et al (1989) A tumour-associated fibronectin isoform generated by alternative splicing of messenger-rna precursors. J Cell Biol 108:1139\u20131148. https:\/\/doi.org\/10.1083\/jcb.108.3.1139","journal-title":"J Cell Biol"},{"key":"477_CR210","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ijc.2910590507","volume":"59","author":"P Castellani","year":"1994","unstructured":"Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G et al (1994) The fibronectin isoform containing the ED-B oncofetal domain\u2014a marker of angiogenesis. Int J Cancer 59:612\u2013618. https:\/\/doi.org\/10.1002\/ijc.2910590507","journal-title":"Int J Cancer"},{"key":"477_CR211","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2174\/1381612043384808","volume":"10","author":"C Ebbinghaus","year":"2004","unstructured":"Ebbinghaus C, Scheuermann J, Neri D, Elia G (2004) Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumour angiogenesis. Curr Pharm Des 10:1537\u20131549. https:\/\/doi.org\/10.2174\/1381612043384808","journal-title":"Curr Pharm Des"},{"key":"477_CR212","doi-asserted-by":"publisher","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","volume":"273","author":"A Pini","year":"1998","unstructured":"Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P et al (1998) Design and use of a phage display library\u2014human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273:21769\u201321776. https:\/\/doi.org\/10.1074\/jbc.273.34.21769","journal-title":"J Biol Chem"},{"key":"477_CR213","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.10662","volume":"102","author":"L Borsi","year":"2002","unstructured":"Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A et al (2002) Selective targeting of tumoural vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102:75\u201385. https:\/\/doi.org\/10.1002\/ijc.10662","journal-title":"Int J Cancer"},{"key":"477_CR214","doi-asserted-by":"publisher","first-page":"7053S","DOI":"10.1158\/1078-0432.CCR-1004-0015","volume":"11","author":"D Berndorff","year":"2005","unstructured":"Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F et al (2005) Radioimmunotherapy of solid tumours by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11:7053S-S7063. https:\/\/doi.org\/10.1158\/1078-0432.CCR-1004-0015","journal-title":"Clin Cancer Res"},{"key":"477_CR215","first-page":"1127","volume":"47","author":"B Tijink","year":"2006","unstructured":"Tijink B, Neri D, Leemans C, Budde M, Dinkelborg L, Stigter-van Walsum M et al (2006) Radioimmunotherapy of head and neck cancer xenografts using I-131-labeled antibody L19-SIP for selective targeting of tumour vasculature. J Nucl Med 47:1127\u20131135","journal-title":"J Nucl Med"},{"key":"477_CR216","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/sj.bjc.6603806","volume":"96","author":"E El-Emir","year":"2007","unstructured":"El-Emir E, Dearling J, Huhalov A, Robson M, Boxer G, Neri D et al (2007) Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer 96:1862\u20131870. https:\/\/doi.org\/10.1038\/sj.bjc.6603806","journal-title":"Br J Cancer"},{"key":"477_CR217","unstructured":"Virotta G, Poli G, Bettini A, Bianchi C, Giovannoni L, Gerali A, et al. Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumours: preliminary results. J Nucl Med. 2012;53"},{"key":"477_CR218","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.seminoncol.2014.07.003","volume":"41","author":"K Dobrenkov","year":"2014","unstructured":"Dobrenkov K, Cheung N (2014) GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol 41:589\u2013612. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.07.003","journal-title":"Semin Oncol"},{"key":"477_CR219","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jnci\/77.3.739","volume":"77","author":"N Cheung","year":"1986","unstructured":"Cheung N, Landmeier B, Neely J, Nelson A, Abramowsky C, Ellery S et al (1986) Complete tumour ablation with radiolabeled-I-131 disialoganglioside GD2-specific monoclonal-antibody against human neuroblastoma xenografted in nude-mice. J Natl Cancer Inst 77:739\u2013745. https:\/\/doi.org\/10.1093\/jnci\/77.3.739","journal-title":"J Natl Cancer Inst"},{"key":"477_CR220","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0940-2993(00)80046-9","volume":"52","author":"H Mennel","year":"2000","unstructured":"Mennel H, Bosslet K, Geissel H, Bauer B (2000) Immunohistochemically visualized localisation of gangliosides G(lac)2 (GD(3)) and G(tri)2 (GD(2)) in cells of human intracranial tumours. Exp Toxicol Pathol 52:277\u2013285","journal-title":"Exp Toxicol Pathol"},{"key":"477_CR221","first-page":"769","volume":"32","author":"S Yeh","year":"1991","unstructured":"Yeh S, Larson S, Burch L, Kushner B, Laquaglia M, Finn R et al (1991) Radioimmunodetection of neuroblastoma with iodine-131-3F8\u2014correlation with biopsy, Iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 32:769\u201376","journal-title":"J Nucl Med"},{"key":"477_CR222","first-page":"2020","volume":"33","author":"S Larson","year":"1992","unstructured":"Larson S, Pentlow K, Volkow N, Wolf A, Finn R, Lambrecht R et al (1992) PET scanning of Iodine-124-3F8 as an approach to tumour dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33:2020\u20132023","journal-title":"J Nucl Med"},{"key":"477_CR223","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"A Yu","year":"2010","unstructured":"Yu A, Gilman A, Ozkaynak M, London W, Kreissman S, Chen H et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324\u20131334. https:\/\/doi.org\/10.1056\/NEJMoa0911123","journal-title":"N Engl J Med"},{"key":"477_CR224","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","volume":"30","author":"N Cheung","year":"2012","unstructured":"Cheung N, Cheung I, Kushner B, Ostrovnaya I, Chamberlain E, Kramer K et al (2012) Murine anti-GD2 monoclonal antibody 3f8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 30:3264\u20133270. https:\/\/doi.org\/10.1200\/JCO.2011.41.3807","journal-title":"J Clin Oncol"},{"key":"477_CR225","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","volume":"97","author":"K Kramer","year":"2010","unstructured":"Kramer K, Kushner B, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P et al (2010) Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 97:409\u2013418. https:\/\/doi.org\/10.1007\/s11060-009-0038-7","journal-title":"J Neurooncol"},{"key":"477_CR226","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26754","author":"K Kramer","year":"2018","unstructured":"Kramer K, Pandit-Taskar N, Humm J, Zanzonico P, Haque S, Dunkel I et al (2018) A phase II study of radioimmunotherapy with intraventricular I-131-3F8 for medulloblastoma. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26754","journal-title":"Pediatr Blood Cancer"},{"key":"477_CR227","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","volume":"25","author":"K Kramer","year":"2007","unstructured":"Kramer K, Humm J, Souweidane M, Zanzonico P, Dunkel I, Gerald W et al (2007) Phase I study of targeted Radioimmunotherapy for leptomeningeal cancers using intra-ommaya 131-I-3F8. J Clin Oncol 25:5465\u20135470. https:\/\/doi.org\/10.1200\/JCO.2007.11.1807","journal-title":"J Clin Oncol"},{"key":"477_CR228","first-page":"5842","volume":"48","author":"A Epstein","year":"1988","unstructured":"Epstein A, Chen F, Taylor C (1988) A novel method for the detection of necrotic lesions in human cancers. Can Res 48:5842\u20135848","journal-title":"Can Res"},{"key":"477_CR229","first-page":"151","volume":"4","author":"A Epstein","year":"1991","unstructured":"Epstein A, Chen D, Ansari A, Najafi A, Siegel M, Lee K et al (1991) Radioimmunodetection of necrotic lesions in human tumours using I-131-labeled TNT-1 F(ab)2 monoclonal-antibody. Antibody Immunoconjug Radiopharmaceut 4:151\u2013161","journal-title":"Antibody Immunoconjug Radiopharmaceut"},{"key":"477_CR230","first-page":"4578","volume":"49","author":"F Chen","year":"1989","unstructured":"Chen F, Taylor C, Epstein A (1989) Tumour necrosis treatment of me-180 human cervical-carcinoma model with i-131-labeled TNT-1 monoclonal-antibody. Can Res 49:4578\u20134585","journal-title":"Can Res"},{"key":"477_CR231","unstructured":"Peregrine Pharmaceuticals Inc. Cotara\u00ae oncology. www.peregrineinc.com\/pipeline\/cotara-oncology.html. Accessed 7 Jan 2021"},{"key":"477_CR232","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2217\/FON.12.58","volume":"8","author":"A Hdeib","year":"2012","unstructured":"Hdeib A, Sloan A (2012) Targeted radioimmunotherapy: the role of I-131-chTNT-1\/B mAb (Cotara (R)) for treatment of high-grade gliomas. Future Oncol 8:659\u2013669. https:\/\/doi.org\/10.2217\/FON.12.58","journal-title":"Future Oncol"},{"key":"477_CR233","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1227\/01.NEU.0000159649.71890.30","volume":"56","author":"S Patel","year":"2005","unstructured":"Patel S, Shapiro W, Laske D, Jensen R, Asher A, Wessels B et al (2005) Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 56:1243\u20131252. https:\/\/doi.org\/10.1227\/01.NEU.0000159649.71890.30","journal-title":"Neurosurgery"},{"key":"477_CR234","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1517\/14712598.6.5.539","volume":"6","author":"W Shapiro","year":"2006","unstructured":"Shapiro W, Carpenter S, Roberts K, Shan J (2006) I-131-chTNT-1\/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther 6:539\u2013545. https:\/\/doi.org\/10.1517\/14712598.6.5.539","journal-title":"Expert Opin Biol Ther"},{"key":"477_CR235","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/cbr.2006.21.243","volume":"21","author":"H Street","year":"2006","unstructured":"Street H, Goris M, Fisher G, Wessels B, Cho C, Hernandez C et al (2006) Phase I study of I-131-chimeric(ch) TNT-1\/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm 21:243\u2013256. https:\/\/doi.org\/10.1089\/cbr.2006.21.243","journal-title":"Cancer Biother Radiopharm"},{"key":"477_CR236","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1200\/JCO.2005.06.108","volume":"23","author":"S Chen","year":"2005","unstructured":"Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S et al (2005) Pivotal study of iodine-131-labeled chimeric tumour necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 23:1538\u20131547. https:\/\/doi.org\/10.1200\/JCO.2005.06.108","journal-title":"J Clin Oncol"},{"key":"477_CR237","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/cbr.2006.21.5","volume":"21","author":"L Yu","year":"2006","unstructured":"Yu L, Ju D, Chen W, Li T, Xu Z, Jiang C et al (2006) I-131-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm 21:5\u201314. https:\/\/doi.org\/10.1089\/cbr.2006.21.5","journal-title":"Cancer Biother Radiopharm"},{"key":"477_CR238","first-page":"297","volume":"1","author":"P Anderson","year":"2003","unstructured":"Anderson P, Wiseman G, Lewis B, Charboneau J, Dunn W, Carpenter S et al (2003) A phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131IchTNT-1\/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Ther 1:297\u2013306","journal-title":"Cancer Ther"},{"key":"477_CR239","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.2035","author":"W Shapiro","year":"2011","unstructured":"Shapiro W, Gupta D, Mahapatra A, Gopal S, Judy K, Patel S et al (2011) Open-label, dose confirmation study of interstitial I-131-chTNT-1\/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: interim results. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2011.29.15_suppl.2035","journal-title":"J Clin Oncol"},{"key":"477_CR240","unstructured":"Peregrine P (2011) Dose confirmation study of cotara for the treatment of glioblastoma multiforme at first relapse. ClinicalTrials.gov NCT00677716. Accessed 7 Jan 2021"},{"key":"477_CR241","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","volume":"101","author":"B Cheson","year":"2003","unstructured":"Cheson B (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391\u2013398. https:\/\/doi.org\/10.1182\/blood-2002-06-1793","journal-title":"Blood"},{"key":"477_CR242","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-16-2523","volume":"77","author":"D Green","year":"2017","unstructured":"Green D, Press O (2017) Whither radioimmunotherapy: to be or not to be? Can Res 77:2191\u20132196. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2523","journal-title":"Can Res"},{"key":"477_CR243","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler L, Hardy R, Schlossman S (1980) Characterization of a human lymphocyte-B-specific antigen. J Immunol 125:1678\u20131685","journal-title":"J Immunol"},{"key":"477_CR244","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","volume":"7","author":"D Einfeld","year":"1988","unstructured":"Einfeld D, Brown J, Valentine M, Clark E, Ledbetter J (1988) Molecular-cloning of the human B-cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711\u2013717. https:\/\/doi.org\/10.1002\/j.1460-2075.1988.tb02867.x","journal-title":"EMBO J"},{"key":"477_CR245","first-page":"4906","volume":"49","author":"O Press","year":"1989","unstructured":"Press O, Farr A, Borroz K, Anderson S, Martin P (1989) Endocytosis and degradation of monoclonal-antibodies targeting human B-cell malignancies. Can Res 49:4906\u20134912","journal-title":"Can Res"},{"key":"477_CR246","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","volume":"83","author":"O Press","year":"1994","unstructured":"Press O, Howellclark J, Anderson S, Bernstein I (1994) Retention of B-CELL-specific monoclonal-antibodies by human lymphoma-cells. Blood 83:1390\u20131397","journal-title":"Blood"},{"key":"477_CR247","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3121\/cmr.3.3.157","volume":"3","author":"AV Rao","year":"2005","unstructured":"Rao AV, Akabani G, Rizzieri DA (2005) Radioimmunotherapy for non-Hodgkin\u2019s lymphoma. Clin Med Res 3:157\u2013165","journal-title":"Clin Med Res"},{"key":"477_CR248","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/107327481201900304","volume":"19","author":"M Tomblyn","year":"2012","unstructured":"Tomblyn M (2012) Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Control 19:196\u2013203. https:\/\/doi.org\/10.1177\/107327481201900304","journal-title":"Cancer Control"},{"key":"477_CR249","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00177","author":"C Bodet-Milin","year":"2013","unstructured":"Bodet-Milin C, Ferrer L, Pallardy A, Eug\u00e8ne T, Rauscher A, Faivre-Chauvet A et al (2013) RIT of B-cell non-Hodgkin\u2019s lymphoma. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2013.00177","journal-title":"Front Oncol"},{"key":"477_CR250","first-page":"6476","volume":"52","author":"D Buchsbaum","year":"1992","unstructured":"Buchsbaum D, Wahl R, Normolle D, Kaminski M (1992) Therapy with unlabeled and I-131-labeled Pan-B-cell monoclonal-antibodies in nude-mice bearing Raji Burkitt\u2019s-lymphoma xenografts. Can Res 52:6476\u20136481","journal-title":"Can Res"},{"key":"477_CR251","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","volume":"14","author":"M Kaminski","year":"1996","unstructured":"Kaminski M, Zasadny K, Francis I, Fenner M, Ross C, Milik A et al (1996) Iodine-131\u2014Anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974\u20131981. https:\/\/doi.org\/10.1200\/JCO.1996.14.7.1974","journal-title":"J Clin Oncol"},{"key":"477_CR252","first-page":"21S","volume":"39","author":"R Wahl","year":"1998","unstructured":"Wahl R, Zasadny K, MacFarlane D, Francis I, Ross C, Estes J et al (1998) Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. J Nucl Med 39:21S-S27","journal-title":"J Nucl Med"},{"key":"477_CR253","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJM199308123290703","volume":"329","author":"M Kaminski","year":"1993","unstructured":"Kaminski M, Zasadny K, Francis I, Milik A, Ross C, Moon S et al (1993) Radioimmunotherapy of B-CELL lymphoma with [I-131] anti-B1 (ANTI-CD20) antibody. N Engl J Med 329:459\u2013465. https:\/\/doi.org\/10.1056\/NEJM199308123290703","journal-title":"N Engl J Med"},{"key":"477_CR254","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259.h8001259_1259_1266","volume":"96","author":"M Kaminski","year":"2000","unstructured":"Kaminski M, Estes J, Zasadny K, Francis I, Ross C, Tuck M et al (2000) Radioimmunotherapy with iodine I-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259\u20131266. https:\/\/doi.org\/10.1182\/blood.V96.4.1259.h8001259_1259_1266","journal-title":"Blood"},{"key":"477_CR255","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","volume":"18","author":"J Vose","year":"2000","unstructured":"Vose J, Wahl R, Saleh M, Rohatiner A, Knox S, Radford J et al (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol 18:1316\u20131323. https:\/\/doi.org\/10.1200\/JCO.2000.18.6.1316","journal-title":"J Clin Oncol"},{"key":"477_CR256","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"M Kaminski","year":"2001","unstructured":"Kaminski M, Zelenetz A, Press O, Saleh M, Leonard J, Fehrenbacher L et al (2001) Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol 19:3918\u20133928. https:\/\/doi.org\/10.1200\/JCO.2001.19.19.3918","journal-title":"J Clin Oncol"},{"key":"477_CR257","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"S Horning","year":"2005","unstructured":"Horning S, Younes A, Jain V, Kroll S, Lucas J, Podoloff D et al (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab. J Clin Oncol 23:712\u2013719. https:\/\/doi.org\/10.1200\/JCO.2005.07.040","journal-title":"J Clin Oncol"},{"key":"477_CR258","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"M Kaminski","year":"2005","unstructured":"Kaminski M, Tuck M, Estes J, Kolstad A, Ross C, Zasadny K et al (2005) I-131-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441\u2013449. https:\/\/doi.org\/10.1056\/NEJMoa041511","journal-title":"N Engl J Med"},{"key":"477_CR259","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1182\/blood.V114.22.3759.3759","volume":"114","author":"M Kaminski","year":"2009","unstructured":"Kaminski M, Tuck M, Estes J, Kolstad A, Ross C, Regan D et al (2009) Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Blood 114:1447. https:\/\/doi.org\/10.1182\/blood.V114.22.3759.3759","journal-title":"Blood"},{"key":"477_CR260","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","volume":"23","author":"J Leonard","year":"2005","unstructured":"Leonard J, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman R et al (2005) Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696\u20135704. https:\/\/doi.org\/10.1200\/JCO.2005.14.803","journal-title":"J Clin Oncol"},{"key":"477_CR261","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","volume":"28","author":"B Link","year":"2010","unstructured":"Link B, Martin P, Kaminski M, Goldsmith S, Coleman M, Leonard J (2010) Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 28:3035\u20133041. https:\/\/doi.org\/10.1200\/JCO.2009.27.8325","journal-title":"J Clin Oncol"},{"key":"477_CR262","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"O Press","year":"2013","unstructured":"Press O, Unger J, Rimsza L, Friedberg J, LeBlanc M, Czuczman M et al (2013) Phase III randomized intergroup trial of CHOP Plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314\u2013320. https:\/\/doi.org\/10.1200\/JCO.2012.42.4101","journal-title":"J Clin Oncol"},{"key":"477_CR263","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3324\/haematol.12120","volume":"93","author":"S Sacchi","year":"2008","unstructured":"Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S et al (2008) Secondary malignancies after treatment for indolent non-Hodgkin\u2019s lymphoma: a 16-year follow-up study. Haematologica 93:398\u2013404. https:\/\/doi.org\/10.3324\/haematol.12120","journal-title":"Haematologica"},{"key":"477_CR264","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood.V118.21.98.98","volume":"118","author":"O Press","year":"2011","unstructured":"Press O, Unger J, Rimsza L, Friedberg J, LeBlanc M, Czuczman M et al (2011) A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab Vs CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin\u2019s lymphoma. Blood 118:48. https:\/\/doi.org\/10.1182\/blood.V118.21.98.98","journal-title":"Blood"},{"key":"477_CR265","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","volume":"102","author":"O Press","year":"2003","unstructured":"Press O, Unger J, Braziel R, Maloney D, Miller T, LeBlanc M et al (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606\u20131612. https:\/\/doi.org\/10.1182\/blood-2003-01-0287","journal-title":"Blood"},{"key":"477_CR266","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"O Press","year":"2006","unstructured":"Press O, Unger J, Braziel R, Maloney D, Miller T, LeBlanc M et al (2006) Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of southwest oncology group protocol S9911. J Clin Oncol 24:4143\u20134149. https:\/\/doi.org\/10.1200\/JCO.2006.05.8198","journal-title":"J Clin Oncol"},{"key":"477_CR267","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2010-02-269753","volume":"117","author":"M Leahy","year":"2011","unstructured":"Leahy M, Turner J (2011) Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with I-131-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117:45\u201352. https:\/\/doi.org\/10.1182\/blood-2010-02-269753","journal-title":"Blood"},{"key":"477_CR268","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood.V118.21.3719.3719","volume":"118","author":"A McQuillan","year":"2011","unstructured":"McQuillan A, Macdonald W, Leahy M, Turner J (2011) First-line radio-immunotherapy of newly diagnosed, advanced follicular non-Hodgkin lymphoma with I-131-rituximab: the INITIAL study. Blood 118:1589","journal-title":"Blood"},{"key":"477_CR269","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.949260","author":"AD McQuillan","year":"2014","unstructured":"McQuillan AD, Macdonald WBG, Turner H (2014) Phase II study first-line Iodine-131-rituximab radioimmunotherapy follicular non-Hodgkin lymphoma and prognostic Fluorine-18 FDG-PET. Leukemia Lymphoma. https:\/\/doi.org\/10.3109\/10428194.2014.949260","journal-title":"Leukemia Lymphoma"},{"key":"477_CR270","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.semnuclmed.2011.12.002","volume":"42","author":"E Silberstein","year":"2012","unstructured":"Silberstein E (2012) Radioiodine: the classic theranostic agent. Semin Nucl Med 42:164\u2013170. https:\/\/doi.org\/10.1053\/j.semnuclmed.2011.12.002","journal-title":"Semin Nucl Med"},{"key":"477_CR271","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.255679","author":"M D'Huyvetter","year":"2020","unstructured":"D\u2019Huyvetter M, De Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux F et al (2020) Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.120.255679","journal-title":"J Nucl Med"},{"key":"477_CR272","unstructured":"Precirix. A study to evaluate safety, tolerability, dosimetry, and preliminary efficacy of the HER2 directed radioligand CAM-H2 in patients with advanced\/metastatic HER2-positive breast, gastric, and gastro-esophageal junction (GEJ) Cancer ClinicalTrials.gov Identifier: NCT04467515; 2020"}],"container-title":["Clinical and Translational Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40336-021-00477-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40336-021-00477-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40336-021-00477-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T14:21:53Z","timestamp":1674397313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40336-021-00477-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":272,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1007\/s40336-021-00477-2","relation":{},"ISSN":["2281-5872","2281-7565"],"issn-type":[{"type":"print","value":"2281-5872"},{"type":"electronic","value":"2281-7565"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Maria-Cristina N Oliveira declares that she has no conflict of interest. Author Jo\u00e3o D. G. Correia declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}